The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications

Jonathan Nash

The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications

Research output: Contribution to conference › Other › peer-review

Abstract

Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. The presentation touches on psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. Current US trials of MDMA-assisted psychotherapy and medical marijuana for treatment-resistant PTSD are focussed on as are patent applications for nasal ketamine sprays for the acutely suicidal. The laws and regulatory procedures governing current clinical research and likely future licensing are considered.

Original language	English
Publication status	Published - 25 Mar 2017
Event	EMDR Association UK & Ireland Annual Conference 2017 - London Duration: 25 Mar 2017 → …

Conference

Conference	EMDR Association UK & Ireland Annual Conference 2017
Period	25/03/17 → …

Keywords

PTSD
psychedelic medicines
legal and policy implications

Cite this

@conference{c0f02277cf4f445e84d51569da4dfff4,

title = "The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications",

abstract = "Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. The presentation touches on psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. Current US trials of MDMA-assisted psychotherapy and medical marijuana for treatment-resistant PTSD are focussed on as are patent applications for nasal ketamine sprays for the acutely suicidal. The laws and regulatory procedures governing current clinical research and likely future licensing are considered.",

keywords = "PTSD, psychedelic medicines, legal and policy implications",

author = "Jonathan Nash",

year = "2017",

month = mar,

day = "25",

language = "English",

note = "EMDR Association UK & Ireland Annual Conference 2017 ; Conference date: 25-03-2017",

}

TY - CONF

T1 - The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications

AU - Nash, Jonathan

PY - 2017/3/25

Y1 - 2017/3/25

N2 - Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. The presentation touches on psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. Current US trials of MDMA-assisted psychotherapy and medical marijuana for treatment-resistant PTSD are focussed on as are patent applications for nasal ketamine sprays for the acutely suicidal. The laws and regulatory procedures governing current clinical research and likely future licensing are considered.

AB - Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. The presentation touches on psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. Current US trials of MDMA-assisted psychotherapy and medical marijuana for treatment-resistant PTSD are focussed on as are patent applications for nasal ketamine sprays for the acutely suicidal. The laws and regulatory procedures governing current clinical research and likely future licensing are considered.

KW - PTSD

KW - psychedelic medicines

KW - legal and policy implications

M3 - Other

T2 - EMDR Association UK & Ireland Annual Conference 2017

Y2 - 25 March 2017

ER -

The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications

Abstract

Conference

Keywords

Fingerprint

Cite this